{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:30:14Z","timestamp":1786343414811,"version":"build-2736575974"},"reference-count":35,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Atopic dermatitis (AD) is a chronic and relapsing skin disorder that significantly impairs patients\u2019 quality of life. Long-term biologic therapy provides durable efficacy for AD, but raises concerns related to costs, safety, and withdrawal-associated relapse. Traditional Chinese medicine (TCM) has a long history in AD treatment and is usually integrated with biologic treatment to achieve complementary benefits and provide comprehensive care for patients with AD. However, high-quality evidence supporting its real-world efficacy remains limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to collect real-world data to evaluate the efficacy and safety of TCM integrated with biologics (TCMIB) in moderate to severe AD, thereby providing methodological insights to obtain high-quality evidence and inform future in-depth research on AD treatment.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 3500 patients with moderate to severe AD will be classified into 7 groups based on clinical manifestations and receive 16 weeks of treatment followed by 36 weeks of observation. A reduction of 75% or more in eczema area and severity index score from baseline to week 16 is set as the primary outcome. The secondary outcomes include the eczema area and severity index, body surface area, Investigator\u2019s Global Assessment scale, Dermatology Life Quality Index, numerical rating scale for pruritus, Patient-Oriented Eczema Measure, Atopic Dermatitis Control Tool, and TCM syndrome scale. Assessments will be performed at baseline, every 2 weeks until week 16, and then every 4 weeks until week 52. Safety assessments include vital signs, concomitant medications, and adverse events. The SAS software (version 9.4) will be used for data analysis, and a\n P<\/jats:italic>\n value of less than .05 will be considered statistically significant.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study has been approved by the institutional review boards of Shanghai Skin Disease Hospital and registered on the International Traditional Medicine Clinical Trial Registry (ITMCTR2025000984). Patient recruitment began in June 2025 and is expected to be completed in January 2028. Data analysis will begin in June 2028. The main results of the study are expected to be submitted for publication in peer-reviewed journals in December 2028.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The anticipated findings of this protocol are projected to furnish strong evidence on the efficacy and safety of TCMIB for moderate to severe AD, potentially contributing to the standardization of TCMIB and optimization of clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/96547","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:08:17Z","timestamp":1786342097000},"page":"e96547-e96547","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Integrated Traditional Chinese Medicine and Biologic Treatment in Moderate to Severe Atopic Dermatitis: Protocol for a Prospective Observational Real-World Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1911-9691","authenticated-orcid":false,"given":"Fanlingzi","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2287-6660","authenticated-orcid":false,"given":"Ruiqi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5605-2692","authenticated-orcid":false,"given":"Jinrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1793-7970","authenticated-orcid":false,"given":"Xiangjin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3733-687X","authenticated-orcid":false,"given":"Wencheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8874","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-5795","authenticated-orcid":false,"given":"Ruiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"4S","key":"R1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?","volume":"139","author":"Bieber","journal-title":"J Allergy Clin Immunol"},{"issue":"10478","key":"R2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","journal-title":"Lancet"},{"issue":"2","key":"R3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100604","article-title":"The prevalence and year lived with disability of atopic dermatitis in China: findings from the Global Burden of Disease Study 2019","volume":"14","author":"Dong","journal-title":"World Allergy Organ J"},{"issue":"1","key":"R5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","journal-title":"J Invest Dermatol"},{"issue":"12","key":"R6","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","article-title":"Burden of atopic dermatitis in adults and adolescents: a systematic literature review","volume":"12","author":"Fasseeh","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"16","key":"R7","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.3390\/jcm12165370","article-title":"Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China","volume":"12","author":"Gu","journal-title":"J Clin Med"},{"issue":"2","key":"R8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.35541\/cjd.20230358","article-title":"Expert consensus on the application and management of therapeutic drugs for atopic dermatitis (2024) [Article in Chinese]","author":"China Dermatologist Association","journal-title":"Chin J Dermatol"},{"issue":"2","key":"R9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.35541\/cjd.20191000","article-title":"Guideline for diagnosis and treatment of atopic dermatitis in China (2020) [Article in Chinese]","volume":"53","author":"Atopic Dermatitis Working Group, Immunology Group, Chinese Society of Dermatology","journal-title":"Chin J Dermatol"},{"issue":"6","key":"R10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.35541\/cjd.20210885","article-title":"Treatment of atopic dermatitis with dupilumab: an expert consensus [Article in Chinese]","volume":"55","author":"Working Group for Atopic Dermatitis, Chinese Society of Dermatology","journal-title":"Chin J Dermatol"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/25785826.2025.2567133","article-title":"A new era in atopic dermatitis treatment and evolving therapeutic strategies","volume":"49","author":"Honda","journal-title":"Immunol Med"},{"issue":"5","key":"R12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"R13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40265-025-02151-7","article-title":"Stapokibart: first approval","volume":"85","author":"Shirley","journal-title":"Drugs"},{"issue":"6","key":"R14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.joim.2025.08.004","article-title":"Clinical practice guidelines for the diagnosis and treatment of atopic dermatitis with integrative traditional Chinese and Western medicine","volume":"23","author":"Du","journal-title":"J Integr Med"},{"issue":"6","key":"R15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/jdv.20534","article-title":"Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how?","volume":"39","author":"Jacobson","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1585368","article-title":"Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis","volume":"12","author":"Chen","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2495831","article-title":"Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab","volume":"36","author":"Trave","journal-title":"J Dermatolog Treat"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1553251","article-title":"Selected traditional Chinese herbal medicines for the treatment of atopic dermatitis - research progress on the effect and mechanism of actions","volume":"16","author":"Zhang","journal-title":"Front Pharmacol"},{"issue":"13","key":"R19","first-page":"1439","volume":"24","author":"Ma","journal-title":"J Clin Exp Med"},{"issue":"4","key":"R20","first-page":"775","volume":"20","author":"Zhang","journal-title":"World J Integr Tradit West Med"},{"key":"R21","unstructured":"Traditional Chinese medicine diagnosis and treatment guidelines for atopic dermatitis [Article in Chinese]. Standardization Administration of China. URL: https:\/\/dbba.sacinfo.org.cn\/attachment\/onlineRead\/c57bc1667445b97c31ae8c7d907f7fa556a5bb0eec1795d4b52a7a17f9d9bc63 [Accessed 29-09-2025]"},{"issue":"1","key":"R22","first-page":"60","volume":"12","author":"Dermatology Professional Committee of the Chinese Association of Traditional Chinese Medicine","journal-title":"Chin J Dermatol Venerol Integr Tradit West Med"},{"issue":"3","key":"R23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index-a practical guide","volume":"33","author":"Hanifin","journal-title":"Dermatitis"},{"issue":"3","key":"R24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/09546630600647297","article-title":"Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis","volume":"17","author":"Siegfried","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"R25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"R26","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01877-8","article-title":"Psychometric properties of the Itch Numeric Rating Scale, Skin Pain Numeric Rating Scale, and Atopic Dermatitis Sleep Scale in adult patients with moderate-to-severe atopic dermatitis","volume":"19","author":"Silverberg","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"R27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective","volume":"140","author":"Charman","journal-title":"Arch Dermatol"},{"issue":"3","key":"R28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","article-title":"Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)","volume":"36","author":"Pariser","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"R29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","journal-title":"Br J Dermatol"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1587977","article-title":"Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Sun","journal-title":"Front Pharmacol"},{"issue":"2","key":"R31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2013.01.019","article-title":"Chinese herbal medicine for atopic dermatitis: a systematic review","volume":"69","author":"Tan","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"R32","first-page":"40","volume":"46","author":"Wang","journal-title":"Shanghai Med Pharm J"},{"issue":"1","key":"R33","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-021-00555-7","article-title":"Compound traditional Chinese medicine dermatitis ointment ameliorates inflammatory responses and dysregulation of itch-related molecules in atopic dermatitis","volume":"17","author":"Zhang","journal-title":"Chin Med"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.726035","article-title":"Huangbai Liniment ameliorates skin inflammation in atopic dermatitis","volume":"12","author":"Zheng","journal-title":"Front Pharmacol"},{"issue":"12","key":"R35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-084788","article-title":"Acupuncture for atopic dermatitis: a systematic review and meta-analysis","volume":"14","author":"Liang","journal-title":"BMJ Open"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:08:19Z","timestamp":1786342099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e96547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2196\/96547","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"v15i4Se96547"}}